Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIG-1273 is a small molecule cosmetic functional ingredient developed by Signum Biosciences, chemically identified as disodium tetramethylhexadecenyl succinoyl cysteine. It is a dual-action isoprenylcysteine (IPC) analog designed to address acne-prone skin and signs of aging. SIG-1273 exhibits antibacterial activity against *Cutibacterium acnes* and provides significant anti-inflammatory effects by antagonizing Toll-like receptor 2 (TLR2) signaling, thereby inhibiting the production of pro-inflammatory cytokines like IL-8. Additionally, it acts as an antioxidant to protect the skin from oxidative stress and environmental damage. The compound is also reported to modulate the lipolysis pathway, contributing to skin-firming benefits. SIG-1273 is utilized as a key active ingredient in topical skincare products, such as those from the Neora and Epicutis brands, for the treatment of blemishes and age-related skin concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SIG-1273.